Small caps to watch: Earnings from Kinaxis, Savaria and Ag Growth with much more to come

The article highlights several small-cap earnings reports that were generally ahead of expectations, led by Kinaxis with Q1 revenue of US$165.6-million versus US$156.3-million expected and adjusted EBITDA of US$53.6-million versus US$43.5-million. Hammond Power Solutions, Sprott, Kits Eyecare, Canfor, Savaria and Ag Growth all posted results that were in line to better than expected, while Ag Growth’s outlook was more cautious due to a 19% decline in order book. The piece is mostly stock-specific but should support near-term moves in individual names, especially where analysts raised targets or reiterated buy ratings.

Analysis

The cleanest read-through is not “small caps are good,” but that capital is rewarding visible cash conversion and punishing balance-sheet duration. The strongest reactions came from names where earnings quality improved faster than the market expected, especially where fee or pricing leverage translated into near-term EBITDA margin expansion. That favors managers and industrials with operating leverage already in place, while leaving slower cyclical recovery stories vulnerable to multiple compression if the macro turns choppy again.

Kinaxis and Sprott both highlight a market that is willing to pay up for self-funding growth when the quarter shows either deferred demand pulling through or recurring economics re-accelerating. The second-order effect is that software and asset-management peers with similar “future promise” narratives but weaker current monetization could lag even if they beat on revenue. In other words, this tape is discriminating between story stocks and businesses that can fund their own AI, product, or distribution expansion without leaning on the equity market.

Ag Growth remains the clearest underperformer in the group because the issue is not just demand, it is financing structure plus working-capital drag. Even if order flow stabilizes, the market may need multiple quarters of deleveraging proof before assigning any rerating. By contrast, HPS looks like the kind of industrial where a higher-quality comp set can justify a sudden multiple reset, and that could spill over to other electrification and transformer exposure if investors start benchmarking on cash generation rather than headline EPS.

The contrarian setup is that the strongest winners may be the names with one-off boosts that investors quickly underwrite into the run-rate. If performance fees, timing benefits, or pull-forwards are doing part of the work, upside can continue for another 1-2 quarters, but the risk/reward worsens after the first post-print rerate. The market is likely underestimating how quickly the bar rises for the next set of reports in a small-cap tape that is already extended.

Key Decisions for Investors

• Go long KXS.TO on any 1-2 day post-earnings consolidation; target a 4-6 week hold. Risk/reward remains favorable if management can preserve guide credibility, but trim if the stock gaps beyond a 12-15% post-print premium.
• Maintain/add to HPS.A.TO versus a basket of lower-quality industrials; 1-3 month horizon. The setup is a rerating-on-ROIC story, with upside if cash conversion continues and downside limited unless margins roll over sharply.
• Avoid or short AFN.TO on strength into the next several weeks. This is a balance-sheet and working-capital story first; any bounce is vulnerable unless backlog and FCF improve together for at least 1-2 quarters.
• Pair long SII against a weaker small-cap asset-manager or fee-sensitive name not yet re-rated; 1-2 month trade. The market is likely to keep rewarding recurring fee growth and operating leverage while punishing names without similar monetization power.
• Fade incremental enthusiasm in KITS.TO unless the next quarter shows upside to guidance, not just in-line results. Use as a tactical short or underweight if the stock re-rates on the quarter, because the guide suggests less near-term operating leverage than the market may be pricing.